

Resource Summary Report

Generated by [dkNET](#) on Sep 12, 2026

BT-20

RRID:CVCL_0178

Type: Cell Line

Proper Citation

RRID:CVCL_0178

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0178

Proper Citation: RRID:CVCL_0178

Description: Cell line BT-20 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Invasive breast carcinoma of no special type

Defining Citation: [PMID:833871](#), [PMID:3518877](#), [PMID:4831449](#), [PMID:6220172](#), [PMID:6582512](#), [PMID:7017212](#), [PMID:7459858](#), [PMID:10969801](#), [PMID:11414198](#), [PMID:11789735](#), [PMID:12661003](#), [PMID:12800145](#), [PMID:13611537](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21778573](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28889351](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: BT-20

Synonyms: BT 20, BT20

Cross References: BTO:BTO_0001466, CLO:CLO_0002041, EFO:EFO_0001092, MCCL:MCC:0000069, CLDB:cl493, CLDB:cl494, CLDB:cl495, ABM:T8959, AddexBio:C0006014/4910, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ATCC:CRL-7912, ATCC:HTB-19, BioSample:SAMN03471671, BioSample:SAMN03472738, BioSample:SAMN10987894, cancercellines:CVCL_0178, CCRID:1101HUM-PUMC000335, Cell_Model_Passport:SIDM00893, ChEMBL-Cells:ChEMBL3307766, ChEMBL-Targets:ChEMBL613870, CLS:300130, Cosmic:687463, Cosmic:871137, Cosmic:904350, Cosmic:906801, Cosmic:934519, Cosmic:979719, Cosmic:991332, Cosmic:997914, Cosmic:1010923, Cosmic:1017159, Cosmic:1018465, Cosmic:1046932, Cosmic:1047701, Cosmic:1136370, Cosmic:1287931, Cosmic:1289382, Cosmic:1434946, Cosmic:1524352, Cosmic:1603190, Cosmic:1609471, Cosmic:1995348, Cosmic:2009507, Cosmic:2036672, Cosmic:2301232, Cosmic:2301522, Cosmic:2307195, Cosmic:2318378, Cosmic:2361352, Cosmic-CLP:906801, DepMap:ACH-000536, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:906801, GEO:GSM184390, GEO:GSM184391, GEO:GSM350505, GEO:GSM421860, GEO:GSM459725, GEO:GSM783945, GEO:GSM827574, GEO:GSM843445, GEO:GSM843446, GEO:GSM847197, GEO:GSM847452, GEO:GSM886891, GEO:GSM887956, GEO:GSM1053689, GEO:GSM1172940, GEO:GSM1238127, GEO:GSM1374406, GEO:GSM1374407, GEO:GSM1401673, GEO:GSM1669629, IARC_TP53:3, IBRC:C10149, IGRhCellID:BT20, KCLB:60061, LiGeA:CCLE_451, LINCS_HMS:50105, LINCS_LDP:LCL-1476, Lonza:114, NCBI_Iran:C434, PharmacDB:BT20_108_2019, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_0178, PubChem_Cell_line:CVCL_0178, SLKBase:3481, TOKU-E:693, Wikidata:Q52392673

ID: CVCL_0178

Record Creation Time: 20220427T215414+0000

Record Last Update: 20260905T174421+0000

Ratings and Alerts

No rating or validation information has been found for BT-20.

Warning: Discontinued: ATCC; CRL-7912

Population: Caucasian., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 921 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Shi J, et al. (2026) TSPYL5 Promotes Triple-Negative Breast Cancer Metastasis by Antagonizing USP10-Mediated PTEN Stabilization to Unleash a ZEB1-Dependent EMT Program. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e20273.

Luo L, et al. (2026) CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. *Nature communications*, 17(1), 619.

Rosado-Sanz M, et al. (2026) Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer. *Oncoimmunology*, 15(1), 2687381.

Karunaraj P, et al. (2026) A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance. *Nature communications*, 17(1).

Boušková V, et al. (2025) Integrative miRNOME profiling reveals the miR-195-5p-CHEK1 axis and its impact on luminal breast cancer outcomes. *Molecular oncology*.

Pinho MP, et al. (2025) Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis. *Cell reports. Medicine*, 6(8), 102252.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. *Cell reports. Medicine*, 6(12), 102478.

Devlin KL, et al. (2025) Growth factors maintain intratumoral heterogeneity and drive therapeutic resistance in triple-negative breast cancer. *Cell reports*, 45(1), 116826.

Nieto-Felipe J, et al. (2025) Notch1 regulates Orai1 and Orai3 expression in breast cancer cells. *Scientific reports*, 16(1), 3229.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. *Frontiers in oncology*, 15, 1549282.

Karunaraj P, et al. (2025) A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug Resistance. *bioRxiv : the preprint server for biology*.

Karunaraj P, et al. (2025) A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug Resistance. *Research square*.

Jeon JH, et al. (2025) Interplay between malic enzyme 2, de novo serine synthesis, and the malate-aspartate shuttle drives metabolic adaptation in triple-negative breast cancer. *Cancer & metabolism*, 13(1), 42.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. *Clinical cancer research : an official journal of the American*

Association for Cancer Research, 31(7), 1275.

Minati R, et al. (2025) CDK4/6 inhibition reprograms the breast cancer immunopeptidome via Rb-dependent chromatin and transcriptomic remodeling. *Cell reports*, 44(12), 116676.

Champagne J, et al. (2025) Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. *Immunity*, 58(1), 247.

Kane MA, et al. (2025) Adhesion strength of tumor cells predicts metastatic disease in vivo. *Cell reports*, 44(3), 115359.

Patel SS, et al. (2025) Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine. *Cancer research communications*, 5(3), 458.

Kai J, et al. (2025) Building simplified cancer subtyping and prediction models with glycan gene signatures. *Cell reports methods*, 5(8), 101140.

Kasama H, et al. (2025) Laeverin is Cell-Surface Target for Liquid-Phase Metastasizing Cancer Cells. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(47), e11349.